What 7 Analyst Ratings Have To Say About Dentsply Sirona
In the preceding three months, 7 analysts have released ratings for Dentsply Sirona (NASDAQ:XRAY), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 2 | 2 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 1 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $14.14, a high estimate of $17.00, and a low estimate of $12.00. A 0.21% drop is evident in the current average compared to the previous average price target of $14.17.
Analyzing Analyst Ratings: A Detailed Breakdown
The perception of Dentsply Sirona by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Cherny | B of A Securities | Raises | Buy | $17.00 | $13.00 |
| Kevin Caliendo | UBS | Lowers | Buy | $16.00 | $17.00 |
| Steven Valiquette | Mizuho | Raises | Neutral | $14.00 | $13.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $14.00 | $14.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $14.00 | $14.00 |
| Jeffrey Johnson | Baird | Lowers | Neutral | $12.00 | $14.00 |
| Glen Santangelo | Barclays | Announces | Underweight | $12.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dentsply Sirona. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Dentsply Sirona compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Dentsply Sirona's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Dentsply Sirona analyst ratings.
Delving into Dentsply Sirona's Background
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (technologically advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors. The remaining portfolio is sold to labs and offices through the firm's salesforce or directly to consumers (such as the Byte clear aligner).
Dentsply Sirona: A Financial Overview
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining Dentsply Sirona's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -4.94% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dentsply Sirona's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -47.23%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Dentsply Sirona's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -24.84%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Dentsply Sirona's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -7.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Dentsply Sirona's debt-to-equity ratio is below the industry average. With a ratio of 1.68, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
How Are Analyst Ratings Determined?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.